Progen Shareholders Seek To Block All-Australia Sale To Avexa
This article was originally published in PharmAsia News
Shareholders of Australia's Progen Pharmaceuticals complain an announced merger with Australian biotech Avexa is seriously flawed and should be canceled. A shareholders group protested at a shareholder briefing the merger would seriously disadvantage Progen, whose U.S. $42.5 million in cash has made it attractive to Avexa as a drug-development partner. Avexa Chairman Nathan Drona said the merger would help it command a higher price for its HIV drug now in trial and valued by an analyst as potentially worth nearly U.S. $350 million. (Click here for more
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.